Movement Alert｜HENGRUI PHARMA Intraday Rise 3.68%, Buyback and Immunology Pipeline Optimism Drive Gains

Market Focus

4 hours ago

On October 8, HENGRUI PHARMA rose 3.68% in regular trading, reaching 50.95 HKD with turnover of 111 million HKD. The move followed a disclosed A-share buyback of 585,000 shares in September for an employee stock ownership plan, signaling management confidence.

JPMorgan maintained an Overweight rating with a 65 HKD target price, noting at least four immunology pipeline candidates could be approved next year. Its core asset SHR-1139 may initiate a large-scale global Phase III trial within the year, potentially the largest such study by a Chinese company in immunology. Earlier licensing of HRS-1596 to Novo Nordisk for up to 2.6 billion USD also reinforced the company's global R&D credibility.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a Chinese company primarily engaged in the research, development, production and sales of pharmaceutical products, focusing on oncology, immunology, metabolic diseases and other therapeutic areas.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/news/1175024169"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1175024169\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1175024169?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-08 09:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175024169","market":"us","top_or_hot":-1,"title":"Movement Alert｜HENGRUI PHARMA Intraday Rise 3.68%, Buyback and Immunology Pipeline Optimism Drive Gains","media":"Market Focus","content":"<p><p>On October 8, HENGRUI PHARMA rose 3.68% in regular trading, reaching 50.95 HKD with turnover of 111 million HKD. The move followed a disclosed A-share buyback of 585,000 shares in September for an employee stock ownership plan, signaling management confidence.</p><p>JPMorgan maintained an Overweight rating with a 65 HKD target price, noting at least four immunology pipeline candidates could be approved next year. Its core asset SHR-1139 may initiate a large-scale global Phase III trial within the year, potentially the largest such study by a Chinese company in immunology. Earlier licensing of HRS-1596 to Novo Nordisk for up to 2.6 billion USD also reinforced the company's global R&D credibility.</p><p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a Chinese company primarily engaged in the research, development, production and sales of pharmaceutical products, focusing on oncology, immunology, metabolic diseases and other therapeutic areas.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HENGRUI PHARMA Intraday Rise 3.68%, Buyback and Immunology Pipeline Optimism Drive Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HENGRUI PHARMA Intraday Rise 3.68%, Buyback and Immunology Pipeline Optimism Drive Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-08 09:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 8, HENGRUI PHARMA rose 3.68% in regular trading, reaching 50.95 HKD with turnover of 111 million HKD. The move followed a disclosed A-share buyback of 585,000 shares in September for an employee stock ownership plan, signaling management confidence.</p><p>JPMorgan maintained an Overweight rating with a 65 HKD target price, noting at least four immunology pipeline candidates could be approved next year. Its core asset SHR-1139 may initiate a large-scale global Phase III trial within the year, potentially the largest such study by a Chinese company in immunology. Earlier licensing of HRS-1596 to Novo Nordisk for up to 2.6 billion USD also reinforced the company's global R&D credibility.</p><p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a Chinese company primarily engaged in the research, development, production and sales of pharmaceutical products, focusing on oncology, immunology, metabolic diseases and other therapeutic areas.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01276","symbol_name":"恒瑞医药","start_time":0,"source_url":"","article_id":"1175024169","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175024169","pubTimestamp":1791424510,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 8, HENGRUI PHARMA rose 3.68% in regular trading, reaching 50.95 HKD with turnover of 111 million HKD. The move followed a disclosed A-share buyback of 585,000 shares in September for an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01276":"恒瑞医药"},"translate_title":"走势提醒|恒瑞医药盘中上涨3.68%，回购和免疫管线乐观情绪推动上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01276":1},"content_text":"On October 8, HENGRUI PHARMA rose 3.68% in regular trading, reaching 50.95 HKD with turnover of 111 million HKD. The move followed a disclosed A-share buyback of 585,000 shares in September for an employee stock ownership plan, signaling management confidence.JPMorgan maintained an Overweight rating with a 65 HKD target price, noting at least four immunology pipeline candidates could be approved next year. Its core asset SHR-1139 may initiate a large-scale global Phase III trial within the year, potentially the largest such study by a Chinese company in immunology. Earlier licensing of HRS-1596 to Novo Nordisk for up to 2.6 billion USD also reinforced the company's global R&D credibility.Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a Chinese company primarily engaged in the research, development, production and sales of pharmaceutical products, focusing on oncology, immunology, metabolic diseases and other therapeutic areas.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}